A device for implanting an artificial vitreous capsule after vitrectomy in ophthalmology.
By implanting an inflatable pouch during vitrectomy, the problem of fluid media being unable to precisely press against the retina is solved, achieving uniform support and pressure control for the retina, improving the safety and comfort of the surgery, and reducing treatment costs.
Patent Information
- Application Number
- CN202522237425.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2025-10-23
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2035-10-23
AI Technical Summary
In current vitrectomy surgeries, the fluid medium cannot precisely and evenly press against the retina, resulting in poor pressure effect, as well as biocompatibility issues and high treatment costs.
An inflatable capsule made of highly elastic biocompatible film material is used. Pressure is applied by implanting the capsule, which includes a capsule body and a tubular inlet section. The pressure inside the capsule is controlled by an infusion system to achieve uniform support for the retina.
It achieves retinal pressure without blind spots, reduces postoperative pain, improves surgical safety and economy, simplifies the surgical procedure, and reduces the risk of complications and treatment costs.
Smart Images

Figure CN224975123U_ABST
Abstract
Description
Technical Field
[0001] This utility model relates to the field of medical device technology, specifically to a device for implanting an artificial vitreous pocket after vitrectomy in ophthalmology. Background Technology
[0002] Retinal detachment and tears are serious blinding eye diseases, and vitrectomy is a key treatment for these conditions. Under normal circumstances, the vitreous cavity within the eyeball is filled with gel-like vitreous humor, and the retina lies smoothly against the choroid lining its inner wall, functioning perfectly (see...). Figure 1 During vitrectomy, when the vitreous humor is removed, the detached retina needs to be removed (see...). Figure 2 Or, the retinal tear can be sealed at its protrusion (see...). Figure 3 ).
[0003] The core objective of the surgery is to reposition the detached retina and close the retinal tear after removing the diseased vitreous humor. Currently, clinical practice primarily uses the method of injecting filler material into the vitreous cavity to achieve pressure, specifically including the following four types: Gas filling: Injecting sterile compressed air or expanding gas (such as S) , The main drawback of this method is that the gas is gradually absorbed by the body, failing to provide sustained pressure, and the expanding gas may cause drastic fluctuations in intraocular pressure postoperatively, resulting in unstable pressure-providing effects. (See...) Figure 4 ) Liquid filling: Injection of perfusion fluids such as balanced salt solutions. The problem is that liquids are fluids, making it difficult to create effective support pressure, and they easily flow into the subretinal space, causing a pressure imbalance above and below the retina, thus failing to achieve effective pressure support. (See...) Figure 5 ) Silicone oil fillers: While silicone oil provides long-term pressure, it exhibits significant biotoxicity and can lead to a series of serious complications, such as emulsification, secondary glaucoma, accelerated corneal endothelial cell decompensation, and cataracts due to contact with the posterior lens capsule. Ultimately, a second surgery is required for removal, a complex process that is difficult to complete. (See...) Figure 6 ) "Heavy water" tamponade: This method uses perfluorocarbon liquid, which sinks due to its high density, to flatten the retina. However, heavy water residue in the eye is highly toxic, and it must be replaced with silicone oil or gas within a certain timeframe. This process is cumbersome and carries the risk of incomplete removal. (See...) Figure 7 ) The aforementioned existing technologies generally suffer from the following common drawbacks: First, the fluid properties prevent them from precisely and uniformly pressing against the entire retinal surface, often resulting in pressure dead zones. When the fluid enters the subretinal space (see...), Figure 8 The pressure on the upper and lower parts of the retina is not uniform, making it impossible to flatten the retina and resulting in poor pressure.
[0004] To ensure that the bubbles or vacuoles act on a specific area, patients must maintain forced postures such as face down or lateral decubitus for extended periods after surgery, significantly increasing their suffering and the difficulty of recovery. (See...) Figure 9 )
[0005] Secondly, the intraocular pressure cannot be precisely controlled, resulting in a significant risk of excessively high or low intraocular pressure. More seriously, the biocompatibility of mediators such as silicone oil and heavy water is a major concern; their toxicity can directly damage retinal function and cause various complications. Finally, these mediators are expensive, and secondary removal surgery is cumbersome, leading to high overall treatment costs and significant uncertainty in prognosis.
[0006] Therefore, there is an urgent need in this field for a new type of pressure device and technical solution that can overcome the above-mentioned defects in order to achieve safer, more effective, more comfortable and more economical treatment results. Utility Model Content
[0007] To address the shortcomings of existing technologies, this invention aims to provide a capsular bag implantation device after vitrectomy. Its core objective is to overcome the limitations of fluid media by implanting an inflatable elastic capsular bag to physically and stably compress the retina, thereby achieving a safer, more effective, and more comfortable treatment outcome.
[0008] To achieve the above objectives, the technical solution adopted by this utility model is: a capsular bag implantation device after vitrectomy, comprising: a capsular bag made of a highly elastic biocompatible film material, the capsular bag including a capsular body portion for containing filler and expanding to press against the retina and a tubular input portion communicating with the capsular body portion; the tubular input portion is used to fill the capsular body portion with filler and to expand the capsular body portion into shape within the vitreous cavity.
[0009] Furthermore, the wall thickness of the capsule portion is less than the wall thickness of the tubular input portion.
[0010] Furthermore, the wall thickness of the capsule portion is 0.02 mm, and the wall thickness of the tubular input portion is 0.05 mm.
[0011] Furthermore, it also includes a clamping member for closing the tubular input section.
[0012] Furthermore, the clamping component is a medical titanium clamp.
[0013] Furthermore, the highly elastic biocompatible film material is medical-grade silicone rubber.
[0014] Furthermore, the capsule portion is configured to expand into a spherical, ellipsoidal, or a specific shape adapted to the shape of the vitreous cavity after being filled with a filler.
[0015] The beneficial effects of this utility model are as follows: 1. Compared to the traditional "fluid compression" method that injects free gas or liquid, this invention uses a precisely controllable "solid capsule" for compression. After inflation, the capsule directly and completely adheres to the inner surface of the retina, forming a uniform support surface. This not only completely solves the problem of compression failure caused by fluid media flowing into the subretinal space, but also, because it can deform and fill the entire vitreous cavity, achieves comprehensive, all-around compression of the retina (including the posterior pole and peripheral ora serrata, areas traditionally difficult to compress). Therefore, patients do not need to maintain forced positions such as face down or lateral lying after surgery, greatly reducing postoperative pain and improving the recovery experience.
[0016] 2. This invention transforms the uncontrollable problem of "fluid dynamics" into a controllable problem of "intracapsular pressure." By simply adjusting the height of the infusion bottle, the doctor can precisely and linearly control the pressure within the capsular bag, much like measuring blood pressure, thereby achieving precise regulation of intraocular pressure. This high degree of pressure controllability effectively avoids optic nerve damage caused by excessively high intraocular pressure or complications caused by excessively low intraocular pressure, greatly improving the safety of the surgery. Furthermore, if the pressure effect is unsatisfactory during the procedure, the filling volume can be adjusted at any time through the infusion system, providing repeatability and reversibility, reducing the risk of surgical errors.
[0017] 3. The capsule of this utility model is made of biocompatible materials such as medical silicone rubber. It exists as a closed whole inside the eye, and the filling material (such as physiological saline) is completely wrapped, which fundamentally eliminates the direct contact between the filling medium and the intraocular tissues (such as the retina, corneal endothelium, and lens).
[0018] 4. This invention can directly utilize conventional and inexpensive irrigation fluid used in surgery as a filler, incurring almost no additional material costs. Compared with expensive expanding gas, silicone oil, or heavy water, it greatly reduces the economic burden on patients. Furthermore, the one-time implantation and eventual complete removal of the device simplify the surgical procedure, avoids the difficulty of completely removing traditional media, leads to better prognosis, and may shorten the overall treatment cycle. Attached Figure Description
[0019] Figure 1 This is a diagram illustrating the normal state of the retina adhering tightly to the inner wall of the vitreous cavity.
[0020] Figure 2 This is a schematic diagram of a retina detaching from the inner wall of the vitreous cavity.
[0021] Figure 3 This is a schematic diagram of a retinal tear.
[0022] Figure 4This is a schematic diagram of injecting sterile compressed air or expanding gas into the vitreous cavity.
[0023] Figure 5 This is a schematic diagram of injecting perfusion fluid into the vitreous cavity.
[0024] Figure 6 This is a schematic diagram of silicone oil being injected into the vitreous cavity.
[0025] Figure 7 This is a schematic diagram of injecting "heavy water" into the vitreous cavity.
[0026] Figure 8 This is a schematic diagram of what happens when fluid enters under the retina.
[0027] Figure 9 This is a diagram illustrating the special position a patient needs to maintain after surgery.
[0028] Figure 10 This is a schematic diagram of the cross-section of the sac.
[0029] Figure 11 It is a schematic diagram of the structure of a bladder after it is filled with liquid or gas and expands dramatically.
[0030] Figure 12 This is a schematic diagram of the titanium clip structure.
[0031] Explanation of reference numerals in the attached diagram: 10, sac; 11, sac body; 12, tubular inlet section; 2, clamping element. Detailed Implementation
[0032] Please see Figure 1-12 As shown in the accompanying drawings, the present invention will be further described in detail below, but the embodiments of the present invention are not limited thereto.
[0033] The specific implementation of the capsular bag implantation device after vitrectomy in ophthalmic surgery according to this utility model first relates to the composition of the device. The core of this device is a capsular bag 10 made of highly elastic, biocompatible medical-grade silicone rubber. The structure of the capsular bag 10 can be referred to... Figure 10The device comprises a thin-walled (preferably 0.02 mm) capsule portion 11 and a thicker-walled (preferably 0.05 mm) tubular input portion 12. This differentiated wall thickness design ensures that the capsule portion 11 expands preferentially and uniformly like a balloon when filled with filler, while the tubular input portion 12 possesses sufficient mechanical strength to facilitate surgical manipulation and clamping. The capsule 10 is available in various sizes according to the nominal expansion diameter of the capsule portion 11 to accommodate different sizes of eyeballs, such as large (a=26 mm), medium (a=24 mm), and small (a=22 mm), while the length of the tubular input portion 12 can be uniformly 15 mm. In addition, the device includes a clamping element 2 for final closure of the tubular input portion 12, which is preferably a biocompatible medical titanium clip.
[0034] It should be noted that the clamping member 2 included in this device for sealing the tubular input section b is a conventional medical titanium clip. This titanium clip is a commercially available, mature standard component; its structure, material, and closing principle are existing technologies and not the innovation of this invention. Therefore, its specific structure will not be described in detail here. The focus of this invention is the innovative design of the pouch 1.
[0035] The specific method of using this device in ophthalmic surgery is as follows: First, the doctor must complete the vitrectomy surgery according to standard procedures and carefully examine the vitreous cavity and retina. Then, the temporary infusion needle is removed, and the sterilized, undamaged capsular device is rolled up and carefully inserted into the vitreous cavity through its infusion incision, ensuring there is no twisting or knotting. Next, the tubing of the surgical infusion system is connected to the tubular input section 12 of the capsular device. Then, the infusion bottle is gradually raised, and the valve is slowly opened to inject sterile infusion fluid (or sterile gas) into the capsular device. At this time, the capsular device 11 begins to gradually expand, and the doctor must closely observe its morphological changes and its contact with the detached retina. When the capsular device begins to partially contact the vitreous cavity wall and support the retina, the raising of the infusion bottle is paused, and the repositioning effect is assessed. If the effect is good, infusion continues slowly. Due to the constraint of the vitreous cavity wall, the capsular device will eventually expand into a shape that matches the vitreous cavity, thereby uniformly pressing the retina back into its original position. During this process, the intracapsular pressure can be easily controlled by precisely adjusting the height of the infusion bottle, thereby precisely controlling the pressure on the top of the eye. It is generally recommended not to exceed the original intraocular pressure level.
[0036] After confirming that the retina has been perfectly repositioned under pressure, the closure procedure can be performed. A medical titanium clip (i.e., clamp 2) is used to firmly clamp the tubular infusion section 12, ensuring no leakage of the filler. Finally, the infusion tubing is removed, and the surgical incision is sutured using standard procedures. The capsular bag remains inside the eye, providing continuous and stable pressure to the retina. Postoperatively, the patient does not need to maintain a special position for an extended period as in traditional surgery (e.g., ...). Figure 9The patient is positioned face down (as shown in the image), which significantly improves comfort. The doctor will instruct the patient to have regular follow-up appointments, typically at 24 hours, 48 hours, one week, and one month, to observe for any abnormalities in the operated eye. Once the retina has fully healed (usually recommended within 6 months), the entire capsular device can be removed through a relatively simple surgery.
[0037] During the procedure, special attention should be paid to the following: Before the operation, it should be confirmed that the patient's fundus has no other specific lesions other than retinal detachment and tear; ensure that the capsular bag is sterile and undamaged, and that the irrigation fluid is sterile; the irrigation pressure must be gradually increased from small to large to avoid a sudden increase in pressure, and strictly controlled below the predetermined safe value; pay attention to the risk of surgical infection; the capsular bag should not remain in the eye for more than 6 months, and the patient should be informed that they need to seek medical attention immediately if any abnormalities occur.
[0038] The above embodiments are merely preferred embodiments of the present utility model and are not intended to limit the scope of the present utility model. Various modifications and improvements made to the technical solutions of the present utility model by those skilled in the art without departing from the spirit of the present utility model should fall within the protection scope defined by the claims of the present utility model.
Claims
1. An ophthalmic post-vitrectomy capsular bag implant device, comprising: include: The sac, made of a highly elastic biocompatible thin film material, includes a sac body for containing filler and expanding to press against the retina, and a tubular inlet communicating with the sac body; the tubular inlet is used to fill the sac body with filler and to expand the sac body into shape within the vitreous cavity.
2. The ophthalmic post-vitrectomy capsular bag implant device of claim 1, wherein: The wall thickness of the capsule portion (11) is less than the wall thickness of the tubular input portion.
3. The ophthalmic post-vitrectomy capsular bag implant device of claim 2, wherein: The wall thickness of the capsule portion is 0.02 mm, and the wall thickness of the tubular input portion is 0.05 mm.
4. The ophthalmic post-vitrectomy capsular bag implant device of claim 1, wherein: It also includes a clamp for closing the tubular input section.
5. The capsular bag implantation device after vitrectomy according to claim 4, characterized in that: The clamping component is a medical titanium clip.
6. The capsular bag implantation device after vitrectomy according to claim 1, characterized in that: The highly elastic biocompatible film material is medical-grade silicone rubber.
7. The capsular bag implantation device after vitrectomy according to claim 1, characterized in that: The capsule is configured to expand into a spherical, ellipsoidal, or other specific shape adapted to the shape of the vitreous cavity after being filled with a filler.
